Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zapping seizures away: targeted brain stimulation offers new hope for epilepsy

NCT ID NCT04782869

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a non-invasive brain stimulation technique called tDCS in 17 people with drug-resistant epilepsy. The stimulation was personalized using prior brain recordings to target the exact area causing seizures. The goal was to see if this approach could safely reduce seizure frequency and improve mood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

17 people

The number who actually took part.

Started

Mar 2021

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Age: Older than 12 years old * Patients with drug-resistant focal epilepsy with no surgical indication or with a previous surgical failure or refusing surgery. * SEEG previously performed before inclusion with an adequate definition of the epileptogenic zone * A clinical or research MRI scan that is suitable for navigated brain stimulation (NBS) and definition of target area. * Number of seizures \>3/month during the baseline (before the first session of tDCS treatment), for at least 3 months * Have stable medications for the whole study duration and few weeks before * Total IQ\>65 * Be able to understand, speak and write in French * Patient, parents or legally representative who have given written informed consent to allow the study data collection procedures, * Be a beneficiary of affiliated to a health insurance plan Exclusion Criteria: * \- Generalized epilepsy * Presenting contraindication to MRI, a serious intercurrent pathology, a progressive brain tumor * Skin conditions (e.g., eczema, lesion) * Any cranial metal implants (excluding \<1 mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant). * Previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm. * Metal inside the head (outside the mouth) such as shrapnel, surgical clips * Patient currently participating in another clinical trial or having participated in a clinical trial in the month prior to inclusion. * Any condition that makes the study subject, in the opinion of the investigator, unsuitable for the study. * Person protected by articles L1121-5, L1121-6 and L1121-8 of Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug-resistant focal epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service d'Epileptologie et de Rythmologie Cérébrale

    Marseille, 13005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.